Porphyrin-copper (II) covalent organic framework nanoplatform with intrinsic bifunctional photodynamic and chemodynamic activities for synergistic multimodal cancer therapy
Aug 2026· Materials Today Bio· Vol 40, pp. 103579· 0 citations· 50 references
Medicine
TL;DR
In vitro and in vivo studies demonstrate that laser-activated HA-TBCOF@DOX effectively suppresses tumor growth, induces apoptosis, and exhibits no apparent systemic toxicity under the tested experimental conditions.
Abstract
Photodynamic therapy (PDT) efficacy is severely compromised by tumor hypoxia and the scarcity of efficient type-I photosensitizers, necessitating multimodal therapeutic strategies. Herein, we report a porphyrin-Cu (II) covalent organic framework (TBCOF) with intrinsic bifunctional photodynamic and chemodynamic activities. Sequential DOX encapsulation and hyaluronic acid (HA) surface functionalization afford HA-TBCOF@DOX, a tumor-targeted nanoplatform integrating four synergistic therapeutic modalities. Under 660 nm laser irradiation, the nanoplatform generates ROS signatures consistent with both type-I and type-II pathways for PDT, while the intrinsic Cu2+ centers are proposed to catalyze a Fenton-like reaction consistent with •OH generation for CDT. Concurrently, observations of O2 evolution suggest catalase-like activity that may decompose endogenous H2O2 into O2, alleviating hypoxia and potentiating oxygen-dependent PDT. Efficient photothermal conversion and pH-triggered DOX release contribute to photothermal and chemotherapeutic effects, respectively, while HA-mediated CD44 targeting enhances cellular uptake and therapeutic specificity. In vitro and in vivo studies demonstrate that laser-activated HA-TBCOF@DOX effectively suppresses tumor growth, induces apoptosis, and exhibits no apparent systemic toxicity under the tested experimental conditions. This work establishes a multifunctional COF-based nanoplatform that addresses PDT limitations observed in this study by integrating intrinsic PDT and CDT, providing a robust strategy for synergistic multimodal cancer therapy.
Porphyrin-based photosensitizers (PSs) are among the most widely explored agents for photodynamic therapy (PDT), yet their clinical translation is severely limited by poor biocompatibility, aggregation-induced quenching, insufficient tumor selectivity, and the intrinsic reactive oxygen species (ROS) resistance of cance...
Yi-Hui Ai, Chong-Zhi Wu, Zhi-Yao Li et al.· Small· 0 citations
In vivo antitumor studies demonstrate that PFD released in situ remodels TME by downregulating hyaluronic acid and type I collagen expression, normalizing tumor vasculature, improving intratumoral oxygen perfusion and contributing to amplified PDT.
Jingjing Jiao, Yibing Wang, Kangkang Huang et al.· Colloids and Surfaces B: Bio...· 0 citations
Cerium molybdate-doped polyaniline nanoparticles are developed to enable a synergistic combination of photothermal therapy (PTT) and CDT, thereby triggering immunogenic cell death (ICD) and enhancing antitumor immunity and presenting a robust nanoplatform integrating chemodynamic and photothermal therapies for potent c...
Shallow tissue penetration of excitation light remains the most persistent barrier to effective photodynamic therapy (PDT), compounded further by tumour hypoxia and elevated glutathione (GSH). Herein, we report a rationally engineered core-shell nanoplatform comprising a Mn-centred porphyrinic metal-organic framework c...
Nilanjana Das, Ushmita Dey, S. Gupta et al.· Dalton Transactions· 0 citations
This work reports a novel strategy for developing a theranostic nanoplatform for long-lasting PDT activated by 1530 nm laser irradiation and glutathione (GSH)-triggered carbon-centered radical synergistic therapy that responds specifically to the TME.
Jitong Gong, Yu Liu, Qing-Kun Yang et al.· ACS Applied Materials and In...· 0 citations
Chemotherapy (CT) suffers from poor selectivity and systemic toxicity, while photodynamic therapy (PDT) and photothermal therapy (PTT) are inherently limited by tumor hypoxia and thermoresistance. Herein, we develop a trimodal synergistic nanoplatform (PDM‐BDP NPs) for ovarian cancer treatment by integrating PDT, mild...
Jia-Qi Wang, Jie Zhang, Dong-Ping Xu et al.· Advanced Healthcare Material...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.